FDA Invites Feedback on Rules for AI-Enabled Medical Devices
FDA published a discussion paper seeking feedback on generative AI medical device regulations.
Why it matters: Health tech developers, legal teams, and regulatory experts must prepare for evolving FDA compliance frameworks for AI-enabled medical devices. This feedback could shape safety standards and innovation pathways.
- On August 18, 2026, FDA released a discussion paper on regulating generative AI medical devices.
- Public comments are accepted until October 19, 2026, via docket FDA-2026-N-7874 on Regulations.gov.
- FDA’s Digital Health Center of Excellence leads this regulatory initiative within the Center for Devices and Radiological Health.
- The paper proposes a two-axis risk assessment and competency-based premarket evaluation framework for these AI devices.
On August 18, 2026, the U.S. Food and Drug Administration (FDA) published a discussion paper titled "Considerations for the Regulation of Generative AI-Enabled Medical Devices." This initiative seeks public input to inform regulatory approaches specifically tailored to the emerging class of generative AI medical devices.
The discussion paper covers key areas: risk assessment using a proposed two-axis framework, premarket evaluation employing a competency-based approach, and postmarket monitoring considerations. It also addresses challenges related to foundation models and agentic AI systems embedded in these devices.
FDA's Digital Health Center of Excellence, part of the Center for Devices and Radiological Health, leads this regulatory effort aimed at ensuring patient safety while encouraging innovation.
The public comment period runs through October 19, 2026, via docket FDA-2026-N-7874 on Regulations.gov. Stakeholders including health tech developers, clinicians, and legal professionals are encouraged to contribute feedback.
FDA Acting Commissioner Kyle Diamantas stated, "Artificial intelligence is transforming medicine, and the United States must lead in shaping how this technology is developed and used safely and responsibly." Meanwhile, Michelle Tarver, M.D., Ph.D., Director of the FDA Center for Devices and Radiological Health, emphasized the need for a regulatory approach that keeps pace with rapid digital health innovation.
This public input will help shape a regulatory framework that is scientifically rigorous, prioritizes patient safety, and aligns with the novel capabilities of generative AI technologies poised to reshape healthcare delivery.
By the numbers:
- August 18, 2026 — Discussion paper release date
- October 19, 2026 — Deadline for public comments
- FDA-2026-N-7874 — Docket number for feedback
Yes, but: Details on implementing the competency-based premarket evaluation remain unspecified in the discussion paper.
What's next: The FDA will review public comments after October 19, 2026, to refine its regulatory approach for AI-enabled medical devices.